Clinical trial
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
NCT00329043 · M.D. Anderson Cancer Center, Other · Active, not recruiting
Key facts
| NCT number | NCT00329043 |
|---|---|
| Title | Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy |
| Official title | A Phase II Neoadjuvant Trial of Sunitinib Malate (SU011248) Plus Hormonal Ablation for Patients Who Have High Risk Localized Prostate Cancer and Will Undergo Prostatectomy |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Pfizer Industry |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug, Procedure |
| Interventions | LHRH Agonist, Sunitinib Malate, Radical Prostatectomy |
| Enrollment | 64 |
| Start date | May 15, 2006 |
| Primary completion | Dec 31, 2027 |
| Completion | Dec 31, 2027 |
| First posted | May 24, 2006 |
| Last update posted | Dec 26, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: